vTv Therapeutics Inc. (VTVT) Buy Target $1.52 – Sell Target $1.68

Trade Setup

Buy Target $1.52Sell Target $1.68
Trailing Stop 20%

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer’s disease.